SABMiller beats revenue expectations
SABMiller, one of the world's largest brewers, managed to beat analysts' sales forecasts in the fist half as its hiked its interim dividend by 12 per cent.
SABMiller, one of the world's largest brewers, managed to beat analysts' sales forecasts in the fist half as its hiked its interim dividend by 12 per cent.
The company reported revenue of $17,476m in the six months to the end of September, up 11% on $15,688m reported the year before, and better than the $16,940m that Charles Stanley was expecting.
However, while SABMiller said that it grew volumes and revenues across most regions during the period, it did admit to a moderation of growth in some emerging markets.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"Development of brands, product ranges and the route to market continued across the breadth of our portfolio supported by further improved operating processes.The acquisition of Foster's in particular has contributed significantly," the firm said.
While profit before tax rose 12% from $2,041m to $2,269m, analysts at Charles Stanley had pencilled in a figure closer of $2,575m.
The interim dividend was raised by 12% from 21.5 cents per share to 24.0 cents per share.
Free cash flow for the period was $1,684m, up 14% year-on-year from $1,479.
"Broad-based revenue and profit growth in the first half reflects the continued success of our approach to the development of our brands, product portfolios, distribution and sales effectiveness," said the group's Chairman Graham Mackay.
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
What the Employment Rights Bill means for your job
New workplace reforms are set to give employees new rights to benefits and flexible working
By Marc Shoffman Published
-
GSK share price surges after $2.2bn Zantac drug settlement
GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer
By Chris Newlands Published